Nine Masts Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Nine Masts Capital’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-113,465	Closed	-$28K	–	281
2026 Q1	$28K	Buy	+113,465	New	+$45.1K	﹤0.01%	222

Other funds holding SGMO

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

AIM

Axiom Investment Management New York $150M AUM

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

HIG

Heritage Investment Group Pompano Beach, Florida $744M AUM 20.51% 1-Year Est. Return

Nine Masts Capital's SGMO Position: Q2 2026 in Review

Nine Masts Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 113,465 shares — an estimated $28K sold.

Nine Masts Capital first reported a position in SGMO in Q1 2026 and held it in 1 quarter. The position peaked at $28K in Q1 2026. 6 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

Nine Masts Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
Nine Masts Capital sold 113,465 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $28K.
Nine Masts Capital first reported a position in SANGAMO THERAPEUTICS INC in Q1 2026 and held it in 1 quarter.
Nine Masts Capital's SANGAMO THERAPEUTICS INC position peaked at $28K in Q1 2026.
6 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.